Esophageal Carcinoma
Conditions
Interventions
Surgery Group:salvage lymphnodes dissection
Radiotherapy Group:Radical cervical lymph node radiotherapy
Sponsors
Affiliated Tumor Hospital of Zhengzhou University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients who have a R0 resection of esophageal carcinoma and 2-field lymph node dissection; 2. Histologic diagnosis of cervical lymph node metastasis, no recurrence or metastasis was found in other organs or parts of the body; 3. Withourt other antineoplastic therapies for metastatic lesions after cervical lymph node metastasis were found; 4. If reoperation is performed, preoperative assessment of metastatic lesions is feasible and radical resection is necessary; 5. Aged 18 to 75 years; 4. Without operative contraindication; 6. The KPS score was higher than 70 without serious medical diseases; 7. All organ function tests can tolerate radiotherapy or reoperation; 8. Absolute white blood cells count =4.0×10^9/L, neutrophil =1.5×10^9/L, platelets =100.0×10^9/L, hemoglobin =90g/L, and normal functions of liver and kidney, total bilirubin(TBIL)=1.5N, aspartate aminotransferase (AST)=2.5N, alanine aminotransferase(ALT)=2.5N, prothrombin time(PT)=1.5N, and activated partial thromboplastin time(APTT) is in normal range, endogenous creatinine clearance rate(CRE)=1.5N; 9. No primary tumor occurred in other sites after radical resection of esophageal carcinoma; 10. ECOG 02; 11. The subjects must understand and sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Multiple primary cancer; 2. Patients with parotid or salivary gland diseases; 3. After radical resection of esophageal cancer, the follow-up time was more than 5 years; 4. Patients with severe emphysema and pulmonary fibrosis; 5. Active infection requiring drug treatment; 6. Patients with bleeding tendency; 7. Patients who are unable to tolerate radiotherapy or reoperation; 8. Previous surgery led to this operation can not be thoroughly lymph node dissection patients; 9. Female patients in pregnancy or lactation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| recurrence rate;response rate;recurrence area;5-year disease free survival; | — |
Countries
China
Contacts
Public ContactYin Li
Outcome results
None listed